Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...

Please provide your email address to receive an email when new articles are posted on . Women who filled a prescription for female hormone therapy did not have an increased risk for retinal vein ...

This interview is a translation of a video blog posted on Medscape France. It has been edited for clarity. Philippe Gabriel Steg, MD: Hello. Today, I would like to address a subject that many ...

COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of ...

Please provide your email address to receive an email when new articles are posted on . A literature search identified 70 eyes with retinal vasculitis or vascular occlusion following brolucizumab for ...

Central retinal artery occlusion (CRAO) is a medical emergency, and systems of care need to evolve to enable prompt recognition, triage, and management in a manner similar to that of cerebral ischemic ...

While most people think of strokes affecting the brain, they can also affect the eye. Central retinal artery occlusion (CRAO) is a rare form of acute ischemic stroke that occurs when blood flow is ...

A real-world safety study found that patients treated with brolucizumab had low occurrences of intraocular inflammation, retinal vascular occlusion, and retinal vasculitis. A study published in ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

Central retinal artery occlusion (CRAO) is a sight‐threatening condition characterised by the abrupt interruption of blood flow to the retina. The resultant ischaemia precipitates sudden, painless ...

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...